Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis

Journal of Pediatric Psychology

Volumn 25, Issue 6, 2000, Pages 403-414

  Quittner, Alexandra L ^a   Sweeny, Sheri ^b   Watrous, Marc ^c   Munzenberger, Paul ^d   Bearss, Karen ^a   Nitza, Amy Gibson ^e   Fisher, Lisa A ^a   Henry, Bernadette ^f  

^a UNIVERSITY OF FLORIDA   (United States)

^b RTI INTERNATIONAL   (United States)

^c GENENTECH INC   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e INDIANA UNIVERSITY   (United States)

^f University of Florida ^*

Author keywords

Cystic fibrosis; Methodology; Pediatric psychology; Quality of life

Indexed keywords

ADOLESCENT; ARTICLE; CHILD PSYCHOLOGY; CLINICAL ARTICLE; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; HUMAN; LINGUISTICS; MALE; METHODOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL CHILD; SEMANTICS; VALIDATION PROCESS;

EID: 0033806096     PISSN: 01468693     EISSN: None     Source Type: Journal    
DOI: 10.1093/jpepsy/25.6.403     Document Type: Article

References (45)

1. Treatment compliance in adults with cystic fibrosis
2. Language and translation issues
3. International use and application of generic health-related quality of life instruments
4. Comparisons of health-related attitudes: A cross national factor analytic study
5. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models
6. Measuring the quality of life before and after bilateral lung transplantation in patients with cystic fibrosis
7. Survival and quality of life of cystic fibrosis patients before and after heart-lung transplantation
8. Cross-cultural instrument equating: Current research and future directions
9. Measurement of quality of well-being in a child and adolescent cystic fibrosis population
10. Heart-lung transplantation for end-stage respiratory disease in patients with cystic fibrosis at Papworth Hospital
11. Identification and assessment of ongoing stressors in adolescents with a chronic illness: An application of the Behavior Analytic Model
12. NHLBI Workshop summary: Clinical behavioral aspects of cystic fibrosis. Directions for future work
13. Integrating economic evaluations and quality of life assessments
14. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
15. Users' guides to the medical literature
16. Evaluating quality of life (QOL) in children with cystic fibrosis (CF): Should we believe the child or the parent?
17. Constructing a disease-specific quality of life questionnaire for children and adults with cystic fibrosis
18. Assessing cross-cultural validity of the Cystic Fibrosis Questionnaire
19. Construction of a disease-specific quality of life questionnaire for cystic fibrosis
20. How to measure quality of life in Cystic Fibrosis (CF) patients across countries and cultures: The Cystic Fibrosis Questionnaire (CFQ)
21. The instability of response sets
22. Measuring quality of life in asthma
23. How to develop and validate a new health-related quality of life instrument
24. The Quality of Well-Being Scale
25. The maximal expiratory flow-volume curve
26. A coding system for appraising questionnaires
27. Critical issues and needs in health-related quality of life assessment in children and adolescents with Chronic health conditions
28. Quality of life as treatment outcome in patients with cystic fibrosis
29. Measuring the quality of well-being in cystic fibrosis and lung transplantation
30. The quality of well-being in cystic fibrosis
31. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis
32. Measurement of quality of life in cystic fibrosis
33. Adherence to medical treatments in adolescents with cystic fibrosis: The development and evaluation of family-based interventions
34. Initial US validation of a disease-specific quality of life (QOL) measure for cystic fibrosis: The Cystic Fibrosis Questionnaire [Abstract]
35. Development of the Role-play Inventory of Situations and Coping Strategies (RISCS) for parents of children with cystic fibrosis
36. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis
37. Outcome measures for clinical trials in cystic fibrosis
38. Introduction
39. Quality of life in cystic fibrosis
40. The PedsQoL: Measurement model for the Pediatric Quality of Life Inventory
41. Evaluating instruments used cross-nationally: Methods from the IQOLA Project